Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease
dc.contributor.author | Pretorius, Etheresia | |
dc.contributor.author | Page, Martin J. | |
dc.contributor.author | Mbotwe, Sthembile | |
dc.contributor.author | Kell, Douglas B. | |
dc.date.accessioned | 2019-10-31T07:53:26Z | |
dc.date.available | 2019-10-31T07:53:26Z | |
dc.date.issued | 2018-03-01 | |
dc.description.abstract | The thrombin-induced polymerisation of fibrinogen to form fibrin is well established as a late stage of blood clotting. It is known that Parkinson's Disease (PD) is accompanied by dysregulation in blood clotting, but it is less widely known as a coagulopathy. In recent work, we showed that the presence of tiny amounts of bacterial lipopolysaccharide (LPS) in healthy individuals could cause clots to adopt an amyloid form, and this could be observed via scanning electron microscopy (SEM) or via the fluorescence of thioflavin-T. This could be prevented by the prior addition of lipopolysaccharide-binding protein (LBP). We had also observed by SEM this unusual clotting in the blood of patients with Parkinson's Disease. We hypothesised, and here show, that this too can be prevented by LBP in the context of PD. This adds further evidence implicating inflammatory microbial cell wall products as an accompaniment to the disease, and may be part of its aetiology. This may lead to novel treatment strategies in PD designed to target microbes and their products. | en_ZA |
dc.description.department | Physiology | en_ZA |
dc.description.librarian | am2019 | en_ZA |
dc.description.sponsorship | The National Research Foundation grant 91548: Competitive Program and South African Medical Research Council to EP, and the Biotechnology and Biological Sciences Research Council Grant BB/L025752/1 to DBK. | en_ZA |
dc.description.uri | http://www.plosone.org | en_ZA |
dc.identifier.citation | Pretorius E, Page MJ, Mbotwe S, Kell DB (2018) Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease. PLoS ONE 13(3): e0192121. https://DOI.org/10.1371/journal.pone.0192121. | en_ZA |
dc.identifier.issn | 1932-6203 (online) | |
dc.identifier.other | 10.1371/journal.pone.0192121 | |
dc.identifier.uri | http://hdl.handle.net/2263/72055 | |
dc.language.iso | en | en_ZA |
dc.publisher | Public Library of Science | en_ZA |
dc.rights | © 2018 Pretorius et al. This is an open access article distributed under the terms of the Creative Commons Attribution License. | en_ZA |
dc.subject | Fibrin | en_ZA |
dc.subject | Coagulopathy | en_ZA |
dc.subject | Lipopolysaccharide-binding protein (LBP) | en_ZA |
dc.subject | Parkinson’s disease (PD) | en_ZA |
dc.subject | Lipopolysaccharide (LPS) | en_ZA |
dc.subject | Scanning electron microscopy (SEM) | en_ZA |
dc.title | Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease | en_ZA |
dc.type | Article | en_ZA |